SEER is an authoratitive source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Monoclonal B-cell neoplasm characterized by nodular or nodular and diffuse, polymorphous proliferation of scattered large neoplastic cells, "popcorn" or L&H (lymphocytic and/or histiocytic) cells. L&H cells reside in large spherical meshworks of follicular dendritic cell process filled with non-neoplastic lymphocytes.
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) commonly involves cervical, axillary, or inguinal lymph nodes. Mediastinal, splenic, and bone marrow involvement are rare. Most patients present with localized peripheral lymphadenopathy (stage I or II). 5-25% of patients present with advanced stage disease. NLPHL represents approximately 5% of all Hodgkin lymphomas. Patients are predominantly male and most frequently in the 30-40 year age group. This disease develops slowly with fairly frequent relapses. It usually remains responsive to therapy and thus is rarely fatal. The prognosis of patients with stage I and stage II disease is very good with 10-year survival in more than 80% of cases. In some countries (France) stage I disease is not treated, especially in children, after resection of the affected lymph nodes.
Advanced stages have unfavorable prognosis. Progression to large B-cell lymphoma-like lesions have been reported.
Preferred primary sites are listed for this disease in the primary site field; however, involvement in other sites is possible, but rare. If you have confirmation that the only involved site is something other than the preferred primary listed, then code to that primary site.